Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Accumulated Expenses: 2023-2025

Historic Accumulated Expenses for Upstream Bio (UPB) over the last 1 years, with Sep 2025 value amounting to $7.2 million.

  • Upstream Bio's Accumulated Expenses rose 36.68% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 36.68%. This contributed to the annual value of $6.0 million for FY2024, which is 33.75% up from last year.
  • As of Q3 2025, Upstream Bio's Accumulated Expenses stood at $7.2 million, which was down 5.56% from $7.7 million recorded in Q2 2025.
  • Upstream Bio's 5-year Accumulated Expenses high stood at $7.7 million for Q2 2025, and its period low was $4.1 million during Q1 2025.
  • Its 3-year average for Accumulated Expenses is $5.8 million, with a median of $5.6 million in 2024.
  • Data for Upstream Bio's Accumulated Expenses shows a peak YoY spiked of 36.68% (in 2025) over the last 5 years.
  • Upstream Bio's Accumulated Expenses (Quarterly) stood at $4.5 million in 2023, then spiked by 33.75% to $6.0 million in 2024, then skyrocketed by 36.68% to $7.2 million in 2025.
  • Its Accumulated Expenses was $7.2 million in Q3 2025, compared to $7.7 million in Q2 2025 and $4.1 million in Q1 2025.